Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2021
Randomized Controlled Trial Multicenter StudyBaricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. ⋯ Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.
-
J. Am. Acad. Dermatol. · Nov 2020
Randomized Controlled TrialBimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Dual neutralization of both interleukin 17A and 17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin 17A alone. ⋯ Bimekizumab response rates were maintained through week 60. A substantial proportion of patients achieved complete skin clearance. Bimekizumab was generally well tolerated.
-
J. Am. Acad. Dermatol. · Apr 2020
Randomized Controlled TrialGreater efficacy of SPF 100+ sunscreen compared with SPF 50+ in sunburn prevention during 5 consecutive days of sunlight exposure: A randomized, double-blind clinical trial.
Beach vacations are high-risk settings for overexposure to ultraviolet radiation. ⋯ SPF 100+ was significantly more effective in protecting against ultraviolet radiation-induced erythema and sunburn than SPF 50+ in actual use in a beach vacation setting.
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialRuxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.
There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects. ⋯ The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialLong-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. ⋯ Brodalumab is well tolerated and showed robust efficacy for more than 2 years.